Boostrix Dosage

Preparation for Administration

Shake vigorously to obtain a homogeneous, turbid, white suspension before administration. Do not use if resuspension does not occur with vigorous shaking. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered. BOOSTRIX should not be combined through reconstitution or mixed with any other vaccine.

Do not administer this product intravenously, intradermally, or subcutaneously.

Dose

BOOSTRIX is administered as a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm.

There are no data to support repeat administration of BOOSTRIX.

Five years should elapse between the last dose of the recommended series of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP) and/or Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (Td) vaccine and the administration of BOOSTRIX.

Additional Dosing Information

Primary Series: The use of BOOSTRIX as a primary series or to complete the primary series for diphtheria, tetanus, or pertussis has not been studied.

Wound Management: Clinicians should refer to guidelines for tetanus prophylaxis in routine wound management.1 Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated should receive a booster dose of a tetanus toxoid-containing vaccine only if they have not received tetanus toxoid within the preceding 10 years. In case of tetanus-prone injury (e.g., wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; avulsions; and wounds resulting from missiles, crushing, burns, and frostbite) in an individual who is in need of tetanus toxoid, BOOSTRIX can be used as an alternative to Td vaccine in patients for whom the pertussis component is also indicated.